Elevated serum cortisol associated with early‐detected increase of brain amyloid deposition in Alzheimer's disease imaging biomarkers among menopausal women: The Framingham Heart Study

Arash Salardini, Jayandra J. Himali, Muhammad Saad Abdullah, Rima Chaudhari, Vanessa M. Young, Eduardo Zilli, Emer R. McGrath, Mitzi M. Gonzales, Emma G. Thibault, Joel Salinas, Hugo J. Aparicio, Dibya Himali, Saptaparni Ghosh, Rachel F. Buckley, Claudia L. Satizábal, Keith A. Johnson, Charles DeCarli, Georges El Fakhri, Ramachandran S. Vasan, Alexa S. Beiser, Sudha SeshadriAlzheimer 2025 · DOI

TL;DR

This study found that higher midlife serum cortisol levels are associated with increased amyloid plaque buildup in the brain 15 years later, but only in post-menopausal women. This suggests cortisol, a stress hormone, may play a role in the early stages of Alzheimer's disease, particularly in women experiencing hormonal changes.

What Problem Does This Paper Address?

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by the accumulation of amyloid-beta (Aβ) plaques and tau tangles in the brain, leading to cognitive decline. While these pathological changes begin years before symptoms appear, many risk factors for AD remain unexplained. Cortisol, a key stress hormone, has been implicated in AD, with some studies linking higher cortisol levels to increased AD risk and cognitive decline. However, findings have been inconsistent, particularly regarding sex differences and the association with tau pathology. This paper aims to clarify the role of midlife cortisol levels in predicting early AD biomarkers (amyloid and tau deposition) in a longitudinal study, with a specific focus on sex and menopausal status, to identify potential early intervention targets.

Methods

The researchers utilized data from the Framingham Heart Study, a well-established, longitudinal cohort study. They analyzed serum cortisol levels collected from 305 cognitively unimpaired participants in middle age. Fifteen years later, these participants underwent positron emission tomography (PET) imaging to measure amyloid-beta (using [¹¹C]PiB) and tau (using [¹⁸F]Flortaucipir) deposition in specific brain regions.

Key methodological aspects include:

  • Longitudinal Design: Following participants over 15 years allows for the investigation of cortisol as a predictor of future AD pathology.
  • PET Imaging: This is a standard, non-invasive technique for quantifying amyloid and tau burden in vivo, providing objective biomarkers of AD pathology.
  • Cortisol Measurement: Fasting serum cortisol was measured in the morning, a standardized approach to capture peak levels.
  • Statistical Modeling: Multivariable regression analyses were employed, adjusting for potential confounders such as age, sex, APOE4 status, and time between cortisol measurement and PET scans. Cortisol was analyzed both continuously and categorized into tertiles to explore linear and non-linear relationships. Interaction terms were used to investigate the influence of sex and menopausal status.

Datasets

The study used data from the Framingham Heart Study (FHS), specifically its third-generation cohort and a multiethnic OMNI cohort. This dataset is well-characterized and has been used in numerous previous studies. No new datasets were introduced.

Key Insights and Ideas

  • Sex-Specific Cortisol Effects: The most striking finding is that elevated midlife cortisol is linked to increased amyloid deposition only in post-menopausal women. This suggests that hormonal changes associated with menopause might make women more vulnerable to the effects of cortisol on brain amyloid accumulation.
  • Amyloid, Not Tau: Cortisol was associated with amyloid deposition but showed no significant association with tau pathology. This aligns with the known temporal sequence of AD pathology, where amyloid accumulation generally precedes tau pathology.
  • Early Detection is Key: The study focused on cognitively unimpaired individuals, highlighting that cortisol's impact can be detected through biomarkers even before cognitive symptoms manifest. This underscores the importance of identifying early risk factors for timely intervention.
  • Menopause as a Modifier: The interaction analysis clearly demonstrated that the association between cortisol and amyloid was significantly amplified in post-menopausal women compared to pre-menopausal women.
  • Cortisol's Role in Preclinical AD: The findings contribute to understanding cortisol's role in the preclinical stages of AD, where interventions might be most effective.

Key Results

  • Elevated midlife serum cortisol was significantly associated with increased amyloid deposition in the posterior cingulate, precuneus, and frontal-lateral regions of the brain in post-menopausal women (p < 0.05).
  • This association was not observed in men or in relation to tau deposition in either sex.
  • The highest tertile of serum cortisol in post-menopausal women was associated with higher amyloid deposition compared to the middle tertile.
  • No significant interactions were found between cortisol levels and APOE4 status for amyloid deposition.

Limitations and Future Work

The authors acknowledge several limitations:

  • Sample Homogeneity: The Framingham Heart Study cohort is predominantly White, limiting the generalizability of the findings to other racial and ethnic groups.
  • Single Cortisol Measurement: Relying on a single morning cortisol measurement might not fully capture long-term cortisol dysregulation. Future studies could benefit from multiple 24-hour urinary or salivary cortisol measurements.
  • Modest Effect Sizes: While statistically significant, the effect sizes for the associations were modest. However, the authors note that these are comparable to other established midlife risk factors for AD.

Future research directions suggested by the authors include:

  • Investigating Sex-Specific Mechanisms: Further research is needed to understand the precise biological pathways that mediate the sex-specific effects of cortisol on AD risk, particularly in post-menopausal women.
  • Exploring Interventions: The findings highlight the potential for interventions targeting cortisol dysregulation or stress reduction for AD prevention, especially in at-risk women.
  • Longitudinal Follow-up: Continued follow-up of this cohort is crucial to determine if these early amyloid changes translate into clinical symptoms and to clarify the causal role of cortisol in AD development.
  • Broader Populations: Future studies should include more diverse populations to ensure generalizability.
  • Exploring Mediators: Investigating the role of lifestyle factors, inflammation, and metabolic dysfunction as potential mediators of the cortisol-AD link is also recommended.

Summary updated

Abstract

High midlife cortisol is linked to increased amyloid deposition in post-menopausal women. Cortisol showed no association with tau pathology. Post-menopausal hormone changes may amplify cortisol's effects on amyloid.
BibTeX
@inproceedings{salardini2025elevated,
  author = {Arash Salardini and Jayandra J. Himali and Muhammad Saad Abdullah and Rima Chaudhari and Vanessa M. Young and Eduardo Zilli and Emer R. McGrath and Mitzi M. Gonzales and Emma G. Thibault and Joel Salinas and Hugo J. Aparicio and Dibya Himali and Saptaparni Ghosh and Rachel F. Buckley and Claudia L. Satizábal and Keith A. Johnson and Charles DeCarli and Georges El Fakhri and Ramachandran S. Vasan and Alexa S. Beiser and Sudha Seshadri},
  title = {{Elevated serum cortisol associated with early‐detected increase of brain amyloid deposition in Alzheimer's disease imaging biomarkers among menopausal women: The Framingham Heart Study}},
  booktitle = {Alzheimer},
  year = {2025},
  doi = {10.1002/alz.70179},
}
Figure